Erratum: Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure (American Journal of Physiology - Lung Cellular and Molecular Physiology (2009) 297, (L1013-L1032) DOI: 10.1152/ajplung.00217.2009);Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 297, Issue 6, 2009, Pages

  Stenmark, Kurt R ^a   Meyrick, Barbara ^a   Galie, Nazzareno ^a   Mooi, Wolter J ^a   McMurtry, Ivan F ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Bone morphogenetic protein; Hypoxia; Inflammation; Progenitor cells

Indexed keywords

CALVASCULIN; ENDOTHELIN RECEPTOR ANTAGONIST; INTERLEUKIN 6; MEMBRANE METALLOENDOPEPTIDASE; MONOCROTALINE; PHOSPHODIESTERASE V INHIBITOR; PRASTERONE; PROSTANOID; RAPAMYCIN; SEMAXANIB; TRIPTOLIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTERY INTIMA PROLIFERATION; CLINICAL FEATURE; DEATH; DISEASE COURSE; DISEASE SEVERITY; HEART FAILURE; HISTOLOGY; HUMAN; HYPOXIA; LUNG ARTERY PRESSURE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW;

ANIMALS; ANOXIA; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION, PULMONARY; NEPRILYSIN; VASOACTIVE INTESTINAL PEPTIDE;

EID: 71949129187     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.zh5-5664-corr.2010     Document Type: Erratum

References (204)

1. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshit A. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94: 385-393, 2004. (Pubitemid 38240731)
2. Ambartsumian N, Klingelhofer J, Grigorian M, Christensen C, Kriajevska M, Tulchinsky E, Georgiev G, Berezin V, Bock E, Rygaard J, Cao R, Cao Y, Lukanidin E. The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. Oncogene 20: 4685-4695, 2001. (Pubitemid 32762440)
3. Ambartsumian N, Klingelhofer J, Grigorian M, Karlstrom O, Sidenius N, Georgiev G, Lukanidin E. Tissue-specific posttranscriptional downregulation of expression of the S100A4(mts1) gene in transgenic animals. Invasion Metastasis 18: 96-104, 1998. (Pubitemid 29276549)
4. Arnett DK, Boland LL, Evans GW, Riley W, Barnes R, Tyroler HA, Heiss G. Hypertension and arterial stiffness: the Atherosclerosis Risk in Communities Study. ARIC Investigators. Am J Hypertens 13: 317-323, 2000. (Pubitemid 30312648)
5. Asosingh K, Aldred MA, Vasanji A, Drazba J, Sharp J, Farver C, Comhair SA, Xu W, Licina L, Huang L, Anand-Apte B, Yoder MC, Tuder RM, Erzurum SC. Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol 172: 615-627, 2008. (Pubitemid 351354535)
6. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105: 1672-1678, 2002. (Pubitemid 34298611)
7. Austin ED, Loyd JE. Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med 28: 43-57, vii-viii, 2007.
8. Baber SR, Deng W, Master RG, Bunnell BA, Taylor BK, Murthy SN, Hyman AL, Kadowitz PJ. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol 292: H1120-H1128, 2007. (Pubitemid 46246966)
9. Badesch BD, Champion HC, Gomez-Sanchez MA, Hoeper M, Loyd J, Manes A, McGoon MD, Naeije R, Olshewski H, Oudiz R, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54: S55-S56, 2009. (Pubitemid 38113518)
10. Bauer NR, Moore TM, McMurtry IF. Rodent models of PAH: are we there yet? Am J Physiol Lung Cell Mol Physiol 293: L580-L582, 2007. (Pubitemid 47358819)
11. Baybutt RC, Herndon BL, Umbehr J, Mein J, Xue Y, Reppert S, Van Dillen C, Kamal R, Halder A, Molteni A. Effects on cytokines and histology by treatment with the ACE inhibitor captopril and the antioxidant retinoic acid in the monocrotaline model of experimentally induced lung fibrosis. Curr Pharm Des 13: 1327-1333, 2007. (Pubitemid 46746370)
12. Benetos A, Rudnichi A, Safar M, Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 32: 560-564, 1998. (Pubitemid 28429149)
13. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetieere P, Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 30: 1410-1415, 1997. (Pubitemid 27528083)
14. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM, Miyazono K, Li E, Bloch KD. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol 287: L1241-L1247, 2004. (Pubitemid 39507203)
15. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Haromy A, Harry G, Moudgil R, McMurtry MS, Weir EK, Archer SL. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 113: 2630-2641, 2006. (Pubitemid 43948012)
16. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 104: 11418-11423, 2007.
17. Bousamra M 2nd, Rossi R, Jacobs E, Parviz M, Busch C, Nelin LD, Haworth S, Dawson CA. Systemic lobar shunting induces advanced pulmonary vasculopathy. J Thorac Cardiovasc Surg 120: 88-98, 2000.
18. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 104: 1184-1191, 2009.
19. Bull TM, Coldren CD, Geraci MW, Voelkel NF. Gene expression profiling in pulmonary hypertension. Proc Am Thorac Soc 4: 117-120, 2007. (Pubitemid 46067570)
20. Burke DL, Frid MG, Kunrath CL, Karoor V, Anwar A, Wagner BD, Strassheim D, Stenmark KR. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol 297: L238-L250, 2009.
21. Burrows B, Harrison RW, Adams WE, Humphreys EM, Long ET, Reimann AF. The postpneumonectomy state: clinical and physiologic observations in thirty-six cases. Am J Med 28: 281-297, 1960.
22. Chae CU, Pfeffer MA, Glynn RJ, Mitchell GF, Taylor JO, Hennekens CH. Increased pulse pressure and risk of heart failure in the elderly. JAMA 281: 634-639, 1999. (Pubitemid 29098064)
23. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 44: 14-30, 2008.
24. Chazova I, Loyd JE, Zhdanov VS, Newman JH, Belenkov Y, Meyrick B. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am J Pathol 146: 389-397, 1995.
25. Chen MY, Cai JT, Du Q, Wang LJ, Chen JM, Shao LM. Reliable experimental model of hepatic veno-occlusive disease caused by monocrotaline. Hepatobiliary Pancreat Dis Int 7: 395-400, 2008.
26. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 16: 13-18, 2005.
27. Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood) 231: 967-973, 2006. (Pubitemid 43845561)
28. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 6: 698-702, 2000. (Pubitemid 30398796)
29. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, Hu F, Ballabh P, Podlutsky A, Losonczy G, de Cabo R, Mathew R, Wolin MS, Ungvari Z. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 54: 668-675, 2009.
30. Cui B, Cheng YS, Dai DZ, Li N, Zhang TT, Dai Y. CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol 36: 169-175, 2009.
31. Das M, Stenmark KR, Ruff LJ, Dempsey EC. Selected isozymes of PKC contribute to augmented growth of fetal and neonatal bovine PA adventitial fibroblasts. Am J Physiol Lung Cell Mol Physiol 273: L1276-L1284, 1997. (Pubitemid 127798011)
32. Davie NJ, Crossno JT Jr, Frid MG, Hofmeister SE, Reeves JT, Hyde DM, Carpenter TC, Brunetti JA, McNiece IK, Stenmark KR. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol 286: L668-L678, 2004.
33. Davies RJ, Morrell NW. Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor. Chest 134: 1271-1277, 2008.
34. de Frutos S, Spangler R, Alo D, Bosc LV. NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin upregulation. J Biol Chem 282: 15081-15089, 2007. (Pubitemid 47093376)
35. Dempsey EC, Das M, Frid MG, Stenmark KR. Unique growth properties of neonatal pulmonary vascular cells: importance of time- and site-specific responses, cell-cell interaction, and synergy. J Perinatol 16: S2-S11, 1996.
36. Dempsey EC, Stenmark KR, McMurtry IF, O'Brien RF, Voelkel NF, Badesch DB. Insulin-like growth factor I and protein kinase C activation stimulate pulmonary artery smooth muscle cell proliferation through separate but synergistic pathways. J Cell Physiol 144: 159-165, 1990. (Pubitemid 20221193)
37. Dempsey EC, Wick MJ, Karoor V, Barr EJ, Tallman DW, Wehling CA, Walchak SJ, Laudi S, Le M, Oka M, Majka S, Cool CD, Fagan KA, Klemm DJ, Hersh LB, Gerard NP, Gerard C, Miller YE. Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia. Am J Pathol 174: 782-796, 2009.
38. Drexler E, Bischoff J, Slifka A, McCowan C, Quinn T, Shandas R, Ivy D, Stenmark K. Stiffening of the extrapulmonary arteries from rats in chronic hypoxic pulmonary hypertension. J Res Natl Inst Stand Technol 113: 239-249, 2008.
39. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 113: 286-295, 2006. (Pubitemid 43754387)
40. Dyer K, Lanning C, Das B, Lee PF, Ivy DD, Valdes-Cruz L, Shandas R. Noninvasive Doppler tissue measurement of pulmonary artery compliance in children with pulmonary hypertension. J Am Soc Echocardiogr 19: 403-412, 2006.
41. 2+ -binding protein family. Genes Dev 3: 1086-1093, 1989.
42. Estrada KD, Chesler NC. Collagen-related gene and protein expression changes in the lung in response to chronic hypoxia. Biomech Model Mechanobiol 8: 263-272, 2009.
43. Fasules JW, Tryka F, Chipman CW, Van Devanter SH. Pulmonary hypertension and arterial changes in calves with a systemic-to-left pulmonary artery connection. J Appl Physiol 77: 867-875, 1994. (Pubitemid 24258324)
44. Faul JL, Nishimura T, Berry GJ, Benson GV, Pearl RG, Kao PN. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 162: 2252-2258, 2000. (Pubitemid 32051697)
45. Frank DB, Lowery J, Anderson L, Brink M, Reese J, de Caestecker M. Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature. Am J Physiol Lung Cell Mol Physiol 294: L98-L109, 2008.
46. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 103: 1245-1249, 2001. (Pubitemid 32221347)
47. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N, Stenmark KR. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 168: 659-669, 2006.
48. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30: 394-403, 2009.
49. Galie N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S, Mariucci E, Donti A, Branzi A, Picchio FM. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs 68: 1049-1066, 2008. (Pubitemid 351693675)
50. Gan CT, Lankhaar JW, Westerhof N, Marcus JT, Becker A, Twisk JW, Boonstra A, Postmus PE, Vonk-Noordegraaf A. Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest 132: 1906-1912, 2007.
51. Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H, Gao B, Loyd JE, Tuder RM, Voelkel NF. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 88: 555-562, 2001. (Pubitemid 32275790)
52. Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 118: 1195-1201, 2008.
53. Greenway S, van Suylen RJ, Du Marchie Sarvaas G, Kwan E, Ambartsumian N, Lukanidin E, Rabinovitch M. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol 164: 253-262, 2004. (Pubitemid 38364609)
54. Guarnieri C, Muscari C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle of monocrotaline-treated rats. Biochem Pharmacol 37: 4685-4688, 1988. (Pubitemid 19006308)
55. Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, Hamon M, Adnot S, Eddahibi S. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111: 2812-2819, 2005. (Pubitemid 40791554)
56. Gust R, Schuster DP. Vascular remodeling in experimentally induced subacute canine pulmonary hypertension. Exp Lung Res 27: 1-12, 2001. (Pubitemid 32056097)
57. Harrison RE, Berger R, Haworth SG, Tulloh R, Mache CJ, Morrell NW, Aldred MA, Trembath RC. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 111: 435-441, 2005. (Pubitemid 40204427)
58. Heath D. The rat is a poor animal model for the study of human pulmonary hypertension. Cardioscience 3: 1-6, 1992.
59. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 18: 533-547, 1958.
60. Heath D, Smith P, Gosney J, Mulcahy D, Fox K, Yacoub M, Harris P. The pathology of the early and late stages of primary pulmonary hypertension. Br Heart J 58: 204-213, 1987. (Pubitemid 17126278)
61. Hemnes AR, Champion HC. Right heart function and haemodynamics in pulmonary hypertension. Int J Clin Pract Suppl: 11-19, 2008. (Pubitemid 352000591)
62. Hirose S, Hosoda Y, Furuya S, Otsuki T, Ikeda E. Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension. Pathol Int 50: 472-479, 2000. (Pubitemid 30482392)
63. Homma N, Nagaoka T, Karoor V, Imamura M, Taraseviciene-Stewart L, Walker LA, Fagan KA, McMurtry IF, Oka M. Involvement of RhoA/Rho kinase signaling in protection against monocrotalineinduced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am J Physiol Lung Cell Mol Physiol 295: L71-L78, 2008.
64. Hong KH, Lee YJ, Lee E, Park SO, Han C, Beppu H, Li E, Raizada MK, Bloch KD, Oh SP. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 118: 722-730, 2008.
65. Hoshikawa Y, Nana-Sinkam P, Moore MD, Sotto-Santiago S, Phang T, Keith RL, Morris KG, Kondo T, Tuder RM, Voelkel NF, Geraci MW. Hypoxia induces different genes in the lungs of rats compared with mice. Physiol Genomics 12: 209-219, 2003. (Pubitemid 37139700)
66. Hsu HH, Ko WJ, Hsu JY, Chen JS, Lee YC, Lai IR, Chen CF. Simvastatin ameliorates established pulmonary hypertension through a heme oxygenase-1 dependent pathway in rats. Respir Res 10: 32, 2009.
67. Humbert M. Update in pulmonary arterial hypertension 2007. Am J Respir Crit Care Med 177: 574-579, 2008.
68. Humbert M. Update in pulmonary hypertension 2008. Am J Respir Crit Care Med 179: 650-656, 2009.
69. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S, 2004.
70. Hunter KS, Lee PF, Lanning CJ, Ivy DD, Kirby KS, Claussen LR, Chan KC, Shandas R. Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension. Am Heart J 155: 166-174, 2008. (Pubitemid 350234769)
71. Ito T, Okada T, Mimuro J, Miyashita H, Uchibori R, Urabe M, Mizukami H, Kume A, Takahashi M, Ikeda U, Sakata Y, Shimada K, Ozawa K. Adenoassociated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats. Hypertension 50: 531-536, 2007. (Pubitemid 47312240)
72. Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, Kangawa K, Kimura H. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 169: 34-38, 2004. (Pubitemid 38233886)
73. Ivy DD, McMurtry IF, Colvin K, Imamura M, Oka M, Lee DS, Gebb S, Jones PL. Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension. Circulation 111: 2988-2996, 2005. (Pubitemid 40814193)
74. Izikki M, Raffestin B, Klar J, Hatzelmann A, Marx D, Tenor H, Zadigue P, Adnot S, Eddahibi S. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats. J Pharmacol Exp Ther 330: 54-62, 2009.
75. Jasmin JF, Lucas M, Cernacek P, Dupuis J. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 103: 314-318, 2001. (Pubitemid 32095421)
76. John Sutton MG, Tajik AJ, McGoon DC. Atrial septal defect in patients ages 60 years or older: operative results and long-term postoperative follow-up. Circulation 64: 402-409, 1981.
77. Jones RC, Capen DE, Cohen KS, Munn LL, Jain RK, Duda DG. A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents. Nat Protoc 3: 388-397, 2008.
78. Kang KK, Ahn GJ, Sohn YS, Ahn BO, Kim WB. DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension. J Int Med Res 31: 517-528, 2003.
79. Kanki-Horimoto S, Horimoto H, Mieno S, Kishida K, Watanabe F, Furuya E, Katsumata T. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 114, Suppl 1: I181-I185, 2006. (Pubitemid 44297148)
80. Kanno S, Wu YJ, Lee PC, Billiar TR, Ho C. Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation 104: 945-950, 2001. (Pubitemid 32778048)
81. Kato T, Kitamura H, Kanisawa M. Comparative effects of isosorbide dinitrate, prednisolone, indomethacin, and elastase on the development of monocrotaline-induced pulmonary hypertension. Exp Mol Pathol 50: 303-315, 1989. (Pubitemid 19166530)
82. Kato T, Nasu T, Sonoda H, Ito KM, Ikeda M, Ito K. Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension. J Cardiovasc Pharmacol 51: 18-23, 2008.
83. Katzenstein AL. Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease. Maryland Heights, MO: Elsevier, 2006.
84. Kay JM, Harris P, Heath D. Pulmonary hypertension produced in rats by ingestion of Crotalaria spectabilis seeds. Thorax 22: 176-179, 1967.
85. Kentera D, Susic D, Veljkovic V, Tucakovic G, Koko V. Pulmonary artery pressure in rats with hereditary platelet function defect. Respiration 54: 110-114, 1988. (Pubitemid 18253463)
86. Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, Weissmann N, Dony E, Savai R, Ghofrani HA, Grimminger F, Busch AE, Schafer S. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 118: 2081-2090, 2008.
87. Kuwano K, Hashino A, Noda K, Kosugi K, Kuwabara K. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6- diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther 326: 691-699, 2008.
88. Kwapiszewska G, Wilhelm J, Wolff S, Laumanns I, Koenig IR, Ziegler A, Seeger W, Bohle RM, Weissmann N, Fink L. Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension. Respir Res 6: 109, 2005. (Pubitemid 41417579)
89. Lammers SR, Kao PH, Qi HJ, Hunter K, Lanning C, Albietz J, Hofmeister S, Mecham R, Stenmark KR, Shandas R. Changes in the structure-function relationship of elastin and its impact on the proximal pulmonary arterial mechanics of hypertensive calves. Am J Physiol Heart Circ Physiol 295: H1451-H1459, 2008.
90. Langleben D, Reid LM. Effect of methylprednisolone on monocrotaline- induced pulmonary vascular disease and right ventricular hypertrophy. Lab Invest 52: 298-303, 1985. (Pubitemid 15144086)
91. Le Cras TD, Kim DH, Gebb S, Markham NE, Shannon JM, Tuder RM, Abman SH. Abnormal lung growth and the development of pulmonary hypertension in the Fawn-Hooded rat. Am J Physiol Lung Cell Mol Physiol 277: L709-L718, 1999. (Pubitemid 29522636)
92. Levy M, Maurey C, Celermajer DS, Vouhe PR, Danel C, Bonnet D, Israel-Biet D. Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. J Am Coll Cardiol 49: 803-810, 2007. (Pubitemid 46240714)
93. Liu D, Wang J, Kinzel B, Mueller M, Mao X, Valdez R, Liu Y, Li E. Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity. Blood 110: 1502-1510, 2007. (Pubitemid 47443965)
94. Liu H, Liu ZY, Guan Q. Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. Interact Cardiovasc Thorac Surg 6: 608-613, 2007. (Pubitemid 47598511)
95. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudarakanchana N, Southwood M, James V, Trembath RC, Morrell NW. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 98: 818-827, 2006. (Pubitemid 43755266)
96. Macchia A, Marchioli R, Marfisi R, Scarano M, Levantesi G, Tavazzi L, Tognoni G. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 153: 1037-1047, 2007. (Pubitemid 46809838)
97. Machado RD, James V, Southwood M, Harrison RE, Atkinson C, Stewart S, Morrell NW, Trembath RC, Aldred MA. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 111: 607-613, 2005. (Pubitemid 40216488)
98. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 47: 799-803, 2006. (Pubitemid 43243104)
99. Majka SM, Skokan M, Wheeler L, Harral J, Gladson S, Burnham E, Loyd JE, Stenmark KR, Varella-Garcia M, West J. Evidence for cell fusion is absent in vascular lesions associated with pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 295: L1028-L1039, 2008.
100. Marecki JC, Cool CD, Parr JE, Beckey VE, Luciw PA, Tarantal AF, Carville A, Shannon RP, Cota-Gomez A, Tuder RM, Voelkel NF, Flores SC. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 174: 437-445, 2006. (Pubitemid 44223125)
101. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53: 1573-1619, 2009.
102. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 115: 1479-1491, 2005.
103. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, Michelakis ED. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 95: 830-840, 2004.
104. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112: 423-431, 2005. (Pubitemid 41022085)
105. Merklinger SL, Wagner RA, Spiekerkoetter E, Hinek A, Knutsen RH, Kabir MG, Desai K, Hacker S, Wang L, Cann GM, Ambartsumian NS, Lukanidin E, Bernstein D, Husain M, Mecham RP, Starcher B, Yanagisawa H, Rabinovitch M. Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. Circ Res 97: 596-604, 2005.
106. Meyrick B. The pathology of pulmonary artery hypertension. Clin Chest Med 22: 393-404, vii, 2001.
107. Meyrick B, Gamble W, Reid L. Development of Crotalaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol Heart Circ Physiol 239: H692-H702, 1980. (Pubitemid 11241499)
108. Meyrick BO, Perkett EA. The sequence of cellular and hemodynamic changes of chronic pulmonary hypertension induced by hypoxia and other stimuli. Am Rev Respir Dis 140: 1486-1489, 1989.
109. Meyrick BO, Reid LM. Crotalaria-induced pulmonary hypertension. Uptake of 3H-thymidine by the cells of the pulmonary circulation and alveolar walls. Am J Pathol 106: 84-94, 1982.
110. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 118: 1486-1495, 2008.
111. Mitani Y, Mutlu A, Russell JC, Brindley DN, DeAlmeida J, Rabinovitch M. Dexfenfluramine protects against pulmonary hypertension in rats. J Appl Physiol 93: 1770-1778, 2002. (Pubitemid 36082991)
112. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline- induced pulmonary hypertension. Circ Res 73: 887-897, 1993. (Pubitemid 23306133)
113. Molteni A, Ward WF, Ts'ao C, Solliday NH. Monocrotaline-induced cardiopulmonary injury in rats: modification by the nonthiol ACE inhibitors CGS13945 and CGS16617. Arch Int Pharmacodyn Ther 291: 21-40, 1988. (Pubitemid 18068223)
114. Mooi WJ, Grungerg K. Histopathology of pulmonary hypertensive diseases. Curr Diagnostic Pathol 12: 429-440, 2006.
115. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain AN, Lang RM, Ratain MJ, Lussier YA, Garcia JG. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 33: 278-291, 2008. (Pubitemid 351629535)
116. Nagaoka T, Gebb SA, Karoor V, Homma N, Morris KG, McMurtry IF, Oka M. Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J Appl Physiol 100: 996-1002, 2006. (Pubitemid 43671557)
117. Nichols W, O'Rourke M. Vascular impedance. In: McDonald's Blood Flow in Arteries. London: Edward Arnold, 1990, p. 283-329.
118. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 166: 1403-1408, 2002. (Pubitemid 35292709)
119. Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG, Kao PN. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 163: 498-502, 2001. (Pubitemid 32158536)
120. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108: 1640-1645, 2003. (Pubitemid 37187793)
121. Nozik-Grayck E, Suliman HB, Majka S, Albietz J, Van Rheen Z, Roush K, Stenmark KR. Lung EC-SOD overexpression attenuates hypoxic induction of Egr-1 and chronic hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 295: L422-L430, 2008.
122. Obata H, Sakai Y, Ohnishi S, Takeshita S, Mori H, Kodama M, Kangawa K, Aizawa Y, Nagaya N. Single injection of a sustainedrelease prostacyclin analog improves pulmonary hypertension in rats. Am J Respir Crit Care Med 177: 195-201, 2008.
123. Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol 151: 1019-1025, 1997. (Pubitemid 27424311)
124. Okada M, Yamashita C, Okada M, Okada K. Establishment of canine pulmonary hypertension with dehydromonocrotaline. Importance of larger animal model for lung transplantation. Transplantation 60: 9-13, 1995.
125. Orton EC, Reeves JT, Stenmark KR. Pulmonary vasodilation with structurally altered pulmonary vessels and pulmonary hypertension. J Appl Physiol 65: 2459-2467, 1988. (Pubitemid 19026407)
126. Overbeek MJ, Vonk MC, Boonstra A, Voskuyl AE, Vonk-Noordegraaf A, Smit EF, Dijkmans BA, Postmus PE, Mooi WJ, Heijdra Y, Grunberg K. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 34: 371-379, 2009.
127. Paddenberg R, Stieger P, von Lilien AL, Faulhammer P, Goldenberg A, Tillmanns HH, Kummer W, Braun-Dullaeus RC. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir Res 8: 15, 2007.
128. Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E, Fishman AP. Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 80: 1207-1221, 1989. (Pubitemid 19282509)
129. Perros F, Dorfmuller P, Souza R, Durand-Gasselin I, Mussot S, Mazmanian M, Herve P, Emilie D, Simonneau G, Humbert M. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J 29: 462-468, 2007. (Pubitemid 46372091)
130. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43: 25S-32S, 2004. (Pubitemid 38759714)
131. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky EH, Brundage BH, Detre KM. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80: 1198-1206, 1989. (Pubitemid 19282508)
132. Prie S, Leung TK, Cernacek P, Ryan JW, Dupuis J. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxypyrimidin-2-yloxy)-3-methoxy-3,3- diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 282: 1312-1318, 1997. (Pubitemid 27408309)
133. Rabinovitch M. Pathobiology of pulmonary hypertension. Annu Rev Pathol 2: 369-399, 2007.
134. Rabinovitch M, Konstam MA, Gamble WJ, Papanicolaou N, Aronovitz MJ, Treves S, Reid L. Changes in pulmonary blood flow affect vascular response to chronic hypoxia in rats. Circ Res 52: 432-441, 1983.
135. Rondelet B, Kerbaul F, Motte S, van Beneden R, Remmelink M, Brimioulle S, McEntee K, Wauthy P, Salmon I, Ketelslegers JM, Naeije R. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 107: 1329-1335, 2003. (Pubitemid 36314419)
136. Roth RA, Dotzlaf LA, Baranyi B, Kuo CH, Hook JB. Effect of monocrotaline ingestion on liver, kidney, and lung of rats. Toxicol Appl Pharmacol 60: 193-203, 1981.
137. Rudolph AM, Neuhauser EB, Golinko RJ, Auld PA. Effects of pneumonectomy on pulmonary circulation in adult and young animals. Circ Res 9: 856-861, 1961.
138. Said SI. The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann NY Acad Sci 1144: 148-153, 2008.
139. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang YP, Chen JJ, Waschek JA, Kort S. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115: 1260-1268, 2007. (Pubitemid 46594770)
140. Sato K, Webb S, Tucker A, Rabinovitch M, O'Brien RF, McMurtry IF, Stelzner TJ. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 145: 793-797, 1992.
141. Satoh M, Satoh A. 3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension. J Pharm Pharm Sci 11: 118s-130s, 2008.
142. Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, Eddahibi S. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 10: 6, 2009.
143. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821, 2005. (Pubitemid 41434408)
144. Senzaki H, Chen CH, Ishido H, Masutani S, Matsunaga T, Taketazu M, Kobayashi T, Sasaki N, Kyo S, Yokote Y. Arterial hemodynamics in patients after Kawasaki disease. Circulation 111: 2119-2125, 2005. (Pubitemid 40577908)
145. Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Sasaki N, Asano H, Kyo S, Yokote Y, Ishizawa A. Ventricular afterload and ventricular work in fontan circulation: comparison with normal two-ventricle circulation and single-ventricle circulation with blalock-taussig shunts. Circulation 105: 2885-2892, 2002. (Pubitemid 34666103)
146. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43: 5S-12S, 2004.
147. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine S, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54: S43-S54, 2009.
148. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111: 3105-3111, 2005. (Pubitemid 40847788)
149. Smith P, Heath D. Electron microscopy of the plexiform lesion. Thorax 34: 177-186, 1979.
150. Smith P, Heath D, Yacoub M, Madden B, Caslin A, Gosney J. The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol 160: 111-121, 1990.
151. Song Y, Jones JE, Beppu H, Keaney JF Jr, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 112: 553-562, 2005. (Pubitemid 41060796)
152. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104: 236-244, 2009.
153. Stenmark KR, Davie N, Frid M, Gerasimovskaya E, Das M. Role of the adventitia in pulmonary vascular remodeling. Physiology 21: 134-145, 2006.
154. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99: 675-691, 2006. (Pubitemid 44498302)
155. Stenmark KR, Fasules J, Hyde DM, Voelkel NF, Henson J, Tucker A, Wilson H, Reeves JT. Severe pulmonary hypertension and arterial adventitial changes in newborn calves at 4,300 m. J Appl Physiol 62: 821-830, 1987. (Pubitemid 17066650)
156. Sun CK, Yuen CM, Kao YH, Chang LT, Chua S, Sheu JJ, Yen CH, Ko SF, Yip HK. Propylthiouracil attenuates monocrotaline-induced pulmonary arterial hypertension in rats. Circ J 73: 1722-1730, 2009.
157. Tada Y, Laudi S, Harral J, Carr M, Ivester C, Tanabe N, Takiguchi Y, Tatsumi K, Kuriyama T, Nichols WC, West J. Murine pulmonary response to chronic hypoxia is strain specific. Exp Lung Res 34: 313-323, 2008. (Pubitemid 351948463)
158. Takenaga K, Nakanishi H, Wada K, Suzuki M, Matsuzaki O, Matsuura A, Endo H. Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas. Clin Cancer Res 3: 2309-2316, 1997. (Pubitemid 28133150)
159. Tanaka Y, Schuster DP, Davis EC, Patterson GA, Botney MD. The role of vascular injury and hemodynamics in rat pulmonary artery remodeling. J Clin Invest 98: 434-442, 1996. (Pubitemid 26255743)
160. Taraseviciene-Stewart L, Gera L, Hirth P, Voelkel NF, Tuder RM, Stewart JM. A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Can J Physiol Pharmacol 80: 269-274, 2002. (Pubitemid 34451241)
161. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427-438, 2001. (Pubitemid 32141434)
162. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 175: 1280-1289, 2007. (Pubitemid 46905754)
163. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 291: L668-L676, 2006. (Pubitemid 44498478)
164. Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, Gera L, Demura Y, Cool C, Kasper M, Voelkel NF. Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides 26: 1292-1300, 2005. (Pubitemid 41021462)
165. Tawara S, Fukumoto Y, Shimokawa H. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 50: 195-200, 2007. (Pubitemid 47267745)
166. Thomson J, Machado R, Pauciulo M, Morgan N, Yacoub M, Corris P, McNeil K, Loyd J, Nichols W, Trembath R. Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein type II receptor. J Heart Lung Transplant 20: 149, 2001.
167. Tofovic SP, Zhang X, Zhu H, Jackson EK, Rafikova O, Petrusevska G. 2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Vascul Pharmacol 48: 174-183, 2008.
168. Tsutsumi Y, Makita T, Yamaguchi K, Shibata O, Sumikawa K. JTV-506, a new K(ATP) channel opener, relaxes pulmonary artery isolated from monocrotaline-treated pulmonary hypertensive rats. J Anesth 18: 210-215, 2004. (Pubitemid 39264214)
169. Tuchscherer HA, Vanderpool RR, Chesler NC. Pulmonary vascular remodeling in isolated mouse lungs: effects on pulsatile pressure-flow relationships. J Biomech 40: 993-1001, 2007.
170. Tuchscherer HA, Webster EB, Chesler NC. Pulmonary vascular resistance and impedance in isolated mouse lungs: effects of pulmonary emboli. Ann Biomed Eng 34: 660-668, 2006.
171. Tuder RM. Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med 30: 376-385, 2009.
172. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, Yacoub M, Polak JM, Voelkel NF. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 195: 367-374, 2001.
173. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med 28: 23-42, vii, 2007.
174. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 36: 130-138, 2000. (Pubitemid 30466123)
175. Vaszar LT, Nishimura T, Storey JD, Zhao G, Qiu D, Faul JL, Pearl RG, Kao PN. Longitudinal transcriptional analysis of developing neointimal vascular occlusion and pulmonary hypertension in rats. Physiol Genomics 17: 150-156, 2004. (Pubitemid 38924161)
176. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114: 1883-1891, 2006.
177. Voelkel NF, Tuder RM. Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? J Clin Invest 106: 733-738, 2000. (Pubitemid 30727588)
178. Wagenvoort CA. Classification of pulmonary vascular lesions in congenital and acquired heart disease. Adv Cardiol 11: 48-55, 1974.
179. Wagenvoort CA. Open lung biopsies in congenital heart disease for evaluation of pulmonary vascular disease. Predictive value with regard to corrective operability. Histopathology 9: 417-436, 1985.
180. Wagenvoort CA. Plexogenic arteriopathy. Thorax 49, Suppl: S39-S45, 1994.
181. Wang YX, Fitch RM. Vascular stiffness: measurements, mechanisms and implications. Curr Vasc Pharmacol 2: 379-384, 2004. (Pubitemid 39200188)
182. Wauthy P, Abdel Kafi S, Mooi WJ, Naeije R, Brimioulle S. Inhaled nitric oxide versus prostacyclin in chronic shunt-induced pulmonary hypertension. J Thorac Cardiovasc Surg 126: 1434-1441, 2003. (Pubitemid 37449170)
183. Weinberg CE, Hertzberg JR, Ivy DD, Kirby KS, Chan KC, Valdes-Cruz L, Shandas R. Extraction of pulmonary vascular compliance, pulmonary vascular resistance, and right ventricular work from single-pressure and Doppler flow measurements in children with pulmonary hypertension: a new method for evaluating reactivity: in vitro and clinical studies. Circulation 110: 2609-2617, 2004. (Pubitemid 39453010)
184. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R, Rodman DM. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 94: 1109-1114, 2004. (Pubitemid 38579706)
185. West J, Harral J, Lane K, Deng Y, Ickes B, Crona D, Albu S, Stewart D, Fagan K. Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am J Physiol Lung Cell Mol Physiol 295: L744-L755, 2008.
186. White RJ. Pulmonary arterial hypertension: building a better mouse trap for 2010. Drug Discov Today Ther Strateg 1: 351-359, 2004.
187. White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, Miller CM, Blaxall BC, Hall CM, Pierce RA, Cool CD, Taubman MB. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293: L583-L590, 2007.
188. Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Eur Respir J 21: 155-176, 2003.
189. Wilson DM, Perkins SN, Thomas JA, Seelig S, Berry SA, Hamm TE Jr, Hoffman AR, Hintz RL, Rosenfeld RG. Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion. Metabolism 38: 57-62, 1989. (Pubitemid 19014383)
190. Wilson DW, Segall HJ, Pan LC, Dunston SK. Progressive inflammatory and structural changes in the pulmonary vasculature of monocrotaline-treated rats. Microvasc Res 38: 57-80, 1989. (Pubitemid 19188539)
191. Xia L, Fu GS, Yang JX, Zhang FR, Wang XX. Endothelial progenitor cells may inhibit apoptosis of pulmonary microvascular endothelial cells: new insights into cell therapy for pulmonary arterial hypertension. Cytotherapy 11: 492-502, 2009.
192. Yaginuma G, Mohri H, Takahashi T. Distribution of arterial lesions and collateral pathways in the pulmonary hypertension of congenital heart disease: a computer aided reconstruction study. Thorax 45: 586-590, 1990. (Pubitemid 20270475)
193. Yamaki S, Wagenvoort CA. Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients. Br Heart J 54: 428-434, 1985. (Pubitemid 16217579)
194. Yamashita T, Sasahara T, Pomeroy SE, Collier G, Nestel PJ. Arterial compliance, blood pressure, plasma leptin, and plasma lipids in women are improved with weight reduction equally with a meat-based diet and a plant-based diet. Metabolism 47: 1308-1314, 1998. (Pubitemid 28523460)
195. Yan SF, Lu J, Xu L, Zou YS, Tongers J, Kisiel W, Mackman N, Pinsky DJ, Stern DM. Pulmonary expression of early growth response-1: biphasic time course and effect of oxygen concentration. J Appl Physiol 88: 2303-2309, 2000. (Pubitemid 30453941)
196. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E, Hansen LA, Park K, Friedman PJ. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 162: 1577-1586, 2000. (Pubitemid 30826189)
197. Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 21: 467-474, 1990.
198. Yuyama H, Fujimori A, Sanagi M, Koakutsu A, Sudoh K, Sasamata M, Miyata K. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. Eur J Pharmacol 496: 129-139, 2004. (Pubitemid 39024325)
199. Zaiman A, Fijalkowska I, Hassoun PM, Tuder RM. One hundred years of research in the pathogenesis of pulmonary hypertension. Am J Respir Cell Mol Biol 33: 425-431, 2005. (Pubitemid 41572684)
200. Zamora MR, Stelzner TJ, Webb S, Panos RJ, Ruff LJ, Dempsey EC. Overexpression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cells from fawn-hooded rats. Am J Physiol Lung Cell Mol Physiol 270: L101-L109, 1996. (Pubitemid 26057336)
201. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96: 442-450, 2005. (Pubitemid 40354538)
202. Zhou H, Liu H, Porvasnik SL, Terada N, Agarwal A, Cheng Y, Visner GA. Heme oxygenase-1 mediates the protective effects of rapamycin in monocrotaline-induced pulmonary hypertension. Lab Invest 86: 62-71, 2006. (Pubitemid 43250969)
203. Zhou KR, Lai YL. α-Difluoromethylornithine attenuates monocrotaline-induced airway/lung dysfunction. J Appl Physiol 72: 1914-1921, 1992.
204. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25: 932-943, 2005. (Pubitemid 40627836)